ClinicalTrials.gg
RecruitingNCT05987592Updated Jun 12, 2026

BE WELL With Migraine: Brain Education and WELLness With Migraine

An interventional study of Brain Education and WELLness with Migraine Group A and Brain Education and WELLness with Migraine Group B in Migraine, sponsored by Wake Forest University Health Sciences. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
286
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 697 studies in Migraine Disorders with a site in United States — 92 open to participants now, 114 under way, 27 of them phase 3. Migraine Disorders · United States.

Planned enrollment
164th of 610
286 · median 78
Started
2024
with 38 others
No phase
204 of 697
31 open now
Primary completion
2027-06
later than 46 of 113 live
Registered
577th of 697
by date

Among the 697 studies in Migraine Disorders with a site in United States, this one is the 164th largest by planned enrollment of the 610 interventional ones that give a count, is one of 39 that started in 2024, is one of 204 with no phase, reaches primary completion later than 46 of the 113 other live ones, and was the 577th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

92 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

87 more — sign in →

All 92 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 697 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

The goal of this randomized clinical trial is to evaluate two different non-drug, virtual treatment options designed to improve the lives of patients with migraine. Both interventions involve 8 weekly sessions and an online platform with additional content and learning. Participants can stay on all their medications during this study. Information from this study may help determine how to better treat migraine.

Read the detailed description

This study involves 8 weekly virtual sessions \& an online platform designed to improve the lives of patients with migraine. Participants from across the United States with migraine may be eligible to participate. This study does not require any in-person visits. All assessments and surveys will be completed virtually and/or online. Participants will independently complete an initial online screen. Participants will attend a scheduled phone or videoconferencing call with a study team member to complete the baseline assessment and learn how to use the online platform. Participants will keep an online daily headache log and complete several online surveys throughout the study.

03

Conditions studied

  • Migraine

Keywords

  • Migraine
  • Migraine without aura
  • Migraine with aura
  • behavioral
  • mind-body
  • integrative
  • virtual
  • online
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of migraine with or without aura by with headache frequency of 4-20 days/month
  • At least 1 year of migraine
  • At least 18 years old
  • Able to participate in 8 weekly online classes
  • Willingness to complete baseline headache logs
  • Headache-related disability (Headache Impact Test (HIT)-6) score >50
  • Fluent in English
  • Completion of technology onboarding with the online platform
  • Pregnant women who are less than or equal to 16 weeks gestation at enrollment are allowed to participate

Exclusion criteria

Exclusion Criteria:

  • Major unstable medical/psychiatric condition that could be unsafe for participants or for the group environment.
  • Medication overuse headache, with migraine treatment
  • Pregnant women who are more than 16 weeks gestation at enrollment
  • Unstable migraine treatment at enrollment: any preventive treatment (oral or injectable medication or neuromodulatory device) started within 12 weeks OR acute treatment within 4 weeks to ensure stability
  • Unwillingness to maintain stable current medication dosages for study duration
  • Failure to complete baseline headache logs
  • Heavy alcohol and illicit drug use
  • Participation in another intervention clinical trial or one that would interfere in this study
  • Experience with stress reduction training (daily meditation practice, regular use of a mindfulness app, or prior experience with MBSR)
  • Any, and all other diagnoses or conditions which, in the opinion of the site investigator, would prevent the patient from being a suitable candidate for the study or interfere with the medical care needs of the study participant: COVID-positive test within 30 days of enrollment
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
286 participants (estimated)

Study arms

  • Experimental
    Brain Education and WELLness with Migraine Group A

    8 weekly virtual sessions plus online platform

    Behavioral: Brain Education and WELLness with Migraine Group A

  • Experimental
    Brain Education and WELLness with Migraine Group B

    8 weekly virtual sessions plus online platform

    Behavioral: Brain Education and WELLness with Migraine Group B

Interventions

  • BehavioralBrain Education and WELLness with Migraine Group A

    Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning

    Also known as: Migraine Group A

  • BehavioralBrain Education and WELLness with Migraine Group B

    Behavioral intervention that involves 8 weekly group virtual sessions with an instructor that may help improve migraine, plus access to an online platform with additional content and learning

    Also known as: Migraine Group B

06

What researchers measure

Primary outcomes

  1. Disability assessed using monthly Migraine Disability Assessment (mMIDAS) - Change in Migraine Disability from baseline to 8 weeks

    Most frequently used headache disability measure developed by Dr. Richard Lipton that captures both presenteeism and absenteeism. Although originally developed to report the prior 3 months, the monthly MIDAS ("mMIDAS") reduces recall bias and improves validity.

    Time frame: Immediately post-intervention at 8 weeks

Secondary outcomes

  1. Depression assessed using Patient Health Questionnaire (PHQ-8) Questionnaire - Change in Depression from baseline to 8 weeks

    PHQ-8 has equivalent diagnostic depression accuracy as PHQ-9 and will be used to assess depression. PHQ-8 scores range from 0 to 24. Each of the 9 items can be scored from 0 ("not at all") to 3 ("nearly every day"). Cut-points of 5, 10, 15, and 20 represent the thresholds for mild, moderate, moderately severe, and severe depression, respectively.

    Time frame: Immediately post-intervention at 8 weeks

  2. Pain Catastrophizing quantified using Pain Catastrophizing Scale (PCS) - Change in Pain catastrophizing from baseline to 8 weeks

    This 13-item scale quantifies an individual's pain experience. Unlike other scales, this does not require for the person to be in pain while completing it. Patients are asked to rate the degree to which they have any of the thoughts described in the questionnaire using a 5-point Likert scale ranging from 0 (never) to 4 (always). The total score is the sum of the scores for the individual items, and ranges from 0 to 52.

    Time frame: Immediately post-intervention at 8 weeks

  3. Self-Efficacy assessed with the Headache Management Self-Efficacy Scale (HMSE) - Change in Self-efficacy from baseline to 8 weeks

    A 25-item scale that assesses patient's beliefs in their ability to prevent and/or appropriately manage their headaches and headache-related disability; it has been shown to be valid and reliable. This scale consists of 25 items rated on a 7-point scale that ranges from 1 strongly disagree to 7 strongly agree. Total scores range from 0-175, higher scores reflect more self-efficacy.

    Time frame: Immediately post-intervention at 8 weeks

  4. Disability assessed using monthly Migraine Disability Assessment (mMIDAS) at 20 weeks - Change in migraine disability from baseline to 20 weeks

    Most frequently used headache disability measure developed by Dr. Richard Lipton that captures both presenteeism and absenteeism. Although originally developed to report the prior 3 months, the monthly MIDAS ("mMIDAS") reduces recall bias and improves validity.

    Time frame: Post-intervention at 20 weeks

  5. Disability assessed using monthly Migraine Disability Assessment (mMIDAS) at 32 weeks - Change in migraine disability from baseline to 32 weeks

    Most frequently used headache disability measure developed by Dr. Richard Lipton that captures both presenteeism and absenteeism. Although originally developed to report the prior 3 months, the monthly MIDAS ("mMIDAS") reduces recall bias and improves validity.

    Time frame: Post-intervention at 32 weeks

  6. Anxiety assessed using Generalized Anxiety Disorder-7 (GAD-7) at 8 weeks - Change in anxiety from baseline to 8 weeks

    This is a 7-item scale that quantifies and assess the severity of generalized anxiety disorder, over the past 2 weeks - GAD-7 score of 0-4 (none), 5-9 (mild), 10-14 (moderate), and 15-21 (severe)

    Time frame: Immediately post-intervention at 8 weeks

  7. Quality of Life assessed using Migraine Specific Quality of Life version 2.1 (MSQL v2.1) at 8 weeks

    This is a 14-item questionnaire that measures how migraines affect a patient's daily life and is a highly reliable and valid instrument. The raw scores are transformed to a 0-100 scale and higher scores reflect greater quality of life

    Time frame: Immediately post-intervention at 8 weeks

  8. Migraine frequency using the daily and 7-day recall headache log at 8 weeks - Change in migraine frequency from baseline to 8 weeks

    Participants will complete a daily headache log (\<10 items) that captures frequency, along with a 7-day recall headache log (\<10 items).

    Time frame: Immediately post-intervention at 8 weeks

07

Study locations

1 of 3 sites recruiting
08

References and documents

Publications

  • Wells RE, Floyd J, O'Brien H, Tamol N, Oliver C, Nelson C, Phillips J, Estave PM, Vaidya S, Moore B, Hamilton K, Adam E, O'Connell N, Moore JB, Lipton RB, Houle TT, Schuman-Olivier Z, Gardiner P, Powers SW; BE WELL with Migraine Champion Providers Network. Building a national headache medicine research network: The BE WELL with Migraine Champion Providers Network. Headache. 2026 Jan;66(1):249-261. doi: 10.1111/head.15065. Epub 2025 Oct 9. PubMed 41065019 ↗

Individual participant data

Plan to share: Yes — De-identified data related to our outcome measures will be included in the IPD Sharing Statement (IPD) sharing plan, in addition to our study protocol, informed consent, and analytic plan.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: After publication and within 12 months of completion of the analysis of study primary aims and ending within 36 months, anonymous and de-identified data will be made available on clinicaltrials.gov so that other investigators can verify or follow-up on the reported analyses.

Access criteria: Investigators whose proposed use of the data has been approved by an IRB identified for this purpose - For individual participant data meta-analysis - Data will be made available on clinicaltrials.gov

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jun 2027, 34 months after the start.

Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 34 months is above that.

Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2023
First posted
Aug 14, 2023
StartActual
Jul 31, 2024
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05987592
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Jul 31, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 12, 2026

Study contacts

Nicole Tamol
Contact
Help4Migraine@wfusm.edu
336-978-1362
Rebecca E Wells, MD, MPH
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion